Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Chief Commercial Officer | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security | Direct | 80,000 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 80,000 · Balance 80,000 F1: On July 31, 2026, the reporting person was granted 80,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2026, the reporting person was granted 80,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 21:03 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantCommon Stock · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025712 · rdgdoc.xml · derivative · entry 1 Erdogan-Trinkaus Ipek · CIK 0002047026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2026, the reporting person was granted 80,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.exercise_date: On July 31, 2026, the reporting person was granted 80,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.expiration_date: On July 31, 2026, the reporting person was granted 80,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:05 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 25,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001292 · rdgdoc.xml · derivative · entry 2 Erdogan-Trinkaus Ipek · CIK 0002047026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,734 Underlying: Common Stock · 25,856 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:05 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,655 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-26-001292 · rdgdoc.xml · derivative · entry 1 Erdogan-Trinkaus Ipek · CIK 0002047026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,878 Underlying: Common Stock · 40,655 shares Expires 2036-01-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 21:57 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Tax withholdingCommon Stock | 85 | $16.90 | $1,436.50 |
DisclosureSEC source: 0001437749-25-037747 · rdgdoc.xml · nonDerivative · entry 1 Erdogan-Trinkaus Ipek · CIK 0002047026 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,403 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2 · price: The shares were sold in multiple trades at prices ranging from $16.90 to $16.91. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.